Albendazole delivery anticancer drug and preparation method thereof

By co-incubating the γ-cyclodextrin organometallic frame with albendazole, a high-solubility albendazole delivery anti-cancer drug was prepared, which solved the problem of poor water solubility of albendazole and significantly improved its bioavailability and anti-tumor effects, achieving effective killing of cancer cells.

CN118987261APending Publication Date: 2024-11-22JILIN UNIVERSITY

Patent Information

Application Number
CN202410956815.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The poor water solubility of albendazole limits its clinical application, resulting in low bioavailability and difficulty in effectively exerting anti-tumor effects.

Method used

The γ-cyclodextrin organometallic frame (γ-CD-MOFs) was used to co-incubate with albendazole, and albendazole was prepared by stirring and centrifugation to deliver anti-cancer drugs to improve their water solubility and bioavailability.

Benefits of technology

The high solubility and biocompatibility of albendazole were achieved, which significantly improved the sensitivity of cancer cells to drugs, significantly inhibited tumor growth, and demonstrated good anti-tumor effects in in vitro and in vitro experiments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987261A_ABST
    Figure CN118987261A_ABST
Patent Text Reader

Abstract

The invention provides an albendazole delivery anti-cancer drug and a preparation method thereof, and belongs to the technical field of biological nano synthesis, ABZ is dissolved in methanol and co-incubated with gamma-CD-MOFs for 24 h, centrifugation is carried out to collect precipitate, drying is carried out to obtain the albendazole delivery anti-cancer drug (MOF-ABZ), and the albendazole delivery anti-cancer drug (MOF-ABZ) is used for preparing the albendazole delivery anti-cancer drug. The purpose of improving the solubility of albendazole by using gamma-cyclodextrin organic metal frameworks (gamma-CD-MOFs) is achieved, and the problem of low bioavailability of ABZ in vivo is solved. In addition, the in-vivo and in-vitro anti-tumor effect of the MOF-ABZ is evaluated through cell and animal experiments, and it is found that the MOF-ABZ can improve the sensitivity of cancer cells to drugs to a certain degree, change the forms of the cells and play a certain killing role on the cancer cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of bionano synthesis. Background Art

[0002] Albendazole (ABZ) is a broad-spectrum anthelmintic in the benzimidazole family, known for its wide range of anti-insect applications. In recent years, ABZ has been repositioned as an anticancer therapeutic agent for liver cancer, colorectal cancer, and ovarian cancer. ABZ exerts its anti-tumor effects from multiple angles, such as inhibiting the cell growth cycle and increasing the oxidative stress response. Studies have shown that albendazole can bind to β-tubulin in the human body and inhibit microtubule polymerization; at the same time, ABZ is an effective inhibitor of vascular endothelial growth factor and angiogenesis, which can regulate tumor metastasis and tumor angiogenesis; in addition, ABZ can induce ROS in the body and induce apoptosis of tumor cells. It can also transform drug-resistant cells into chemotherapy-sensitive cells, reduce cell resistance, and has an immunomodulatory effect. However, the poor water solubility of albendazole limits its clinical application. Therefore, it is of great significance to improve the water solubility of albendazole and increase the bioavailability of ABZ.

[0003] Cyclodextrin and its derivatives are one of the hot topics in pharmaceutical chemistry research. Cyclodextrin organic metal frameworks (CD-MOFs) prepared from food-grade cyclodextrin (CDs) and metal ions are non-toxic and water-soluble, and are "green" nanomaterials with potential medical applications. CD-MOFs have a porous surface and regular morphology, and have excellent drug loading potential. According to reports, CD-MOFs have been successfully used to improve drugs with poor water solubility such as ibuprofen, triptolide, and resveratrol, and have achieved good drug loading effects. The types of CD-MOFs are divided into α-CD-MOFs, β-CD-MOFs, and γ-CD-MOFs. Among them, γ-CD-MOFs can improve the stability of drugs while having a high loading rate. Summary of the invention

[0004] In order to improve the water solubility of albendazole and increase the bioavailability of ABZ, the present invention proposes a method for preparing an albendazole-delivered anticancer drug. The technical solution adopted by the present invention is as follows:

[0005] A method for preparing an anticancer drug delivered by albendazole, comprising the following steps:

[0006] 1) Dissolve 10-11 mg of albendazole in 50 mL of methanol and add 500 mg of γ-CD-MOF into a container and stir for 18-24 hours;

[0007] 2) Collect the precipitate by centrifugation and wash it with anhydrous ethanol for 3 times to obtain the albendazole delivery anticancer drug. The centrifugal speed in step 2 is 8000 rpm.

[0008] The preparation method of γ-CD-MOFs described in the present invention is as follows:

[0009] 1) Under continuous stirring, add 810 mg of γ-CD and 280 mg of potassium hydroxide into 25 mL of pure water, filter using a 0.45 μm water filter membrane, and place the mother liquor in a 100 mL beaker for later use;

[0010] 2) Place the 100mL beaker containing the mother liquor in a 250mL beaker containing 30mL of anhydrous methanol. Seal the 250mL beaker with a sealing film and transfer it to a 40℃ water bath to react for 6h;

[0011] 3) After the reaction is complete, the liquid in the 100mL beaker is filtered through a 0.45μm water filter membrane again to remove the crystals in the liquid. Dissolve 200mg PEG-20000 in 25mL methanol, mix with the above filtrate, and let stand for 12 to 24 hours;

[0012] 4) The static liquid was centrifuged at 8000 rpm for 20 min, washed three times with anhydrous methanol, and dried at 50° C. under vacuum conditions for 12 h to obtain γ-CD-MOFs.

[0013] Beneficial effects of the present invention:

[0014] The present invention first evaluates the biosafety of γ-CD-MOFs, and finds that γ-CD-MOFs are green, safe, and non-toxic biomaterials through cell proliferation and death experiments, live-death cell death experiments, and hemolysis experiments, and has good biocompatibility. The present invention dissolves ABZ in methanol and incubates it with γ-CD-MOFs for 24 hours, collects the precipitate by centrifugation, and obtains albendazole delivery anticancer drug (MOF-ABZ) after drying, thereby achieving the purpose of using γ-cyclodextrin organic metal framework (γ-CD-MOFs) to improve the solubility of albendazole, and solves the problem of low bioavailability of ABZ in vivo.

[0015] The present invention also evaluated the anti-tumor effect of MOF-ABZ in vitro and in vivo through cell and animal experiments, and found that MOF-ABZ can increase the ROS in cancer cells to a certain extent, thereby increasing the sensitivity of cancer cells to drugs and playing a role in tumor killing. 6 H22 cells were injected into the right armpit of mice to construct a mouse H22 liver cancer model, which was then treated with MOF-ABZ. It was found that MOF-ABZ could exert an anti-tumor effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 is a scanning electron microscope image of γ-CD-MOFs prepared by the present invention;

[0017] Figure 2 It is a Fourier transform infrared spectrum (FTIR) diagram of γ-CD-MOFs loaded with albendazole prepared by the present invention;

[0018] Figure 3 is the anti-tumor growth curve of the present invention;

[0019] Figure 4 It is the anti-tumor effect diagram of the present invention;

[0020] Figure 5 is a graph of tumor growth inhibition rate of the present invention;

[0021] Figure 6 This is a HE staining picture of the internal organs of experimental mice after the drug is administered in vivo. DETAILED DESCRIPTION

[0022] The technical solution of the present invention is further explained and illustrated in the form of specific embodiments below.

[0023] Example 1

[0024] The specific steps of the preparation method of γ-CD-MOF loaded albendazole are as follows:

[0025] In the first step, 810 mg of γ-CD and 280 mg of potassium hydroxide were added to 25 mL of pure water under continuous stirring, and filtered using a 0.45 μm water filter membrane to obtain a mother liquor which was placed in a 100 mL beaker for later use;

[0026] In the second step, the 100 mL beaker containing the mother liquor was placed in a 250 mL beaker containing 30 mL of anhydrous methanol. The 250 mL beaker was sealed with a sealing film and then transferred to a 40 °C water bath for reaction for 6 h.

[0027] Step 3: After the reaction is complete, the liquid in the 100 mL beaker is filtered through a 0.45 μm water filter membrane again to remove the crystals in the liquid. Dissolve 200 mg of PEG-20000 in 25 mL of methanol, mix with the above filtrate, and let stand overnight;

[0028] Step 4: On the second day, the static liquid was centrifuged at 8000 rpm for 20 min, washed three times with anhydrous methanol, and dried under vacuum at 50 °C for 12 h to obtain γ-CD-MOFs.

[0029] Step 5: 10.8 mg of albendazole was dissolved in 50 mL of methanol and placed in a 100 mL beaker with 500 mg of γ-CD-MOF and stirred overnight.

[0030] Step 6. The next day, the precipitate was collected by centrifugation at 8000 rpm and washed three times with anhydrous ethanol to obtain MOF-ABZ.

[0031] Effect verification

[0032] 1. Characterization Experiment

[0033] The synthesized material γ-CD-MOFs was evenly dispersed in anhydrous ethanol, and the sample was dropped onto a silicon wafer and characterized using SEM (JSM-IT500A). Figure 1 .like Figure 1 As shown, γ-CD-MOFs exhibit a cubic crystal structure with an average crystal size of about 750 nm.

[0034] Take the dried powder γ-CD-MOFs, ABZ and MOF-ABZ 1-2mg and 100-200mg spectrally pure KBr powder, mix and grind, put into a die, and press on a tablet press while evacuating to make a transparent sheet with a thickness of about 1mm and a diameter of about 10mm. After collecting the background, the sample was analyzed using a Fourier transform infrared spectrometer iS10, and the results were Figure 2 .

[0035] like Figure 2 As shown, the characteristic functional group peaks of γ-CD-MOF include 1105, 1123, 1405, 1837, 3181 cm -1 etc., among which 3000-3600cm -1 The -OH stretching vibration of γ-CD-MOF is responsible for the -1 The γ-CD-MOF is caused by the CH bending vibration and CH2 shear vibration of the saturated hydrocarbon group; 1000~1300cm -1 The left and right sides are caused by the single bond COC vibration of γ-CD-MOF. The characteristic functional group peaks of albendazole include 3328, 2956, 1635, 1416, 1326, 1193, 791 cm-1, etc., among which the peaks at 3100-3500 cm -1 The -NH stretching vibration of the ABZ amide group is caused by the -NH stretching vibration of the ABZ amide group; at 1600 cm -1 Around 1420-1400cm, representing the stretching vibration of C=N bond -1 2800-3000cm-1 due to the -CH bending vibration of the ABZ amide group -1It is caused by the CH bending vibration of the saturated hydrocarbon group of ABZ; there are a large number of peaks in the ABZ infrared image, and the blend has peaks of both MOF and ABZ. The disappearance of the ABZ characteristic peak in MOF-ABZ may be due to a large amount of ABZ entering the MOF cavity, which causes the ABZ characteristic peak to be covered up. A large amount of ABZ loaded in the MOF cavity may partially destroy the structure of MOF and cause ABZ molecules to appear on the surface of MOF, resulting in the appearance of characteristic peaks belonging to ABZ at 1600-2000cm-1.

[0036] 2. Animal experiments

[0037] In this study, 6-week-old BALB / c mice were selected as the animal model, and H22 cells were injected subcutaneously into the armpits of the mice. 3 All mice were randomly divided into the following seven groups for peritumoral injection: (1) phosphate buffered saline (PBS), (2) γ-CD-MOF, (3) ABZ, (4) MOF-ABZ, (5) doxorubicin (DOX), (6) DOX / ABZ and (7) DOX / MOF-ABZ. A total of seven injections were performed continuously from day 1 to day 15. The dose of DOX was 2 mg / kg per mouse, and the dose of ABZ was 0.5 mg / kg. The doses of γ-CD-MOF and MOF-ABZ were 50 mg / kg. The doses of all preparations were kept consistent for each injection. The tumor volume of mice was measured every two days. The formula for calculating the tumor volume was Vtumor = 4 / 3πL×W×H, where L, W and H represent the length, width and height of the tumor, respectively. The volume data were collected for Figure 3 , Figure 3 The growth curve of the tumor during the whole experiment. After 14 days of treatment, the mice were euthanized and the tumors were removed and photographed. Figure 4 .Depend on Figure 3 ,4 It can be seen that compared with the material group and the simple drug administration group, MOF-ABZ has a better tumor treatment effect, and the tumor inhibition rate of MOF-ABZ is 58.7% ( Figure 5 The main organs of mice (heart, liver, spleen, lung and kidney) were stained with hematoxylin and eosin (H&E). Figure 6 ), the results showed that the cell structure and morphology of the main organs in each group were normal, indicating that MOF-ABZ can inhibit tumor growth without damaging the body.

Claims

1. A method for preparing albendazole for delivering anticancer drugs, It is characterized in that The method comprises the following steps: 1) Dissolve 10-11 mg of albendazole in 50 mL of methanol and add 500 mg of γ-CD-MOF into a container and stir for 18-24 hours; 2) Collecting the precipitate by centrifugation and washing it with anhydrous ethanol to obtain the albendazole-delivered anticancer drug.

2. The method for preparing the albendazole-delivered anticancer drug according to claim 1, It is characterized in that In step 2), the centrifugal speed is 8000 rpm.

3. The method for preparing the albendazole-delivered anticancer drug according to claim 1, It is characterized in that Albendazole is 10.8 mg.

4. The method for preparing the albendazole-delivered anticancer drug according to claim 1, It is characterized in that The preparation method of the γ-CD-MOFs is as follows: 1) Under continuous stirring, add 810 mg of γ-CD and 280 mg of potassium hydroxide into 25 mL of pure water, filter using a 0.45 μm water filter membrane, and place the mother liquor in a 100 mL beaker for later use; 2) Place the 100mL beaker containing the mother liquor in a 250mL beaker containing 30mL of anhydrous methanol. Seal the 250mL beaker with a sealing film and transfer it to a 40℃ water bath to react for 6h; 3) After the reaction is complete, the liquid in the 100mL beaker is filtered through a 0.45μm water filter membrane again to remove the crystals in the liquid. Dissolve 200mg PEG-20000 in 25mL methanol, mix with the above filtrate, and let stand for 8 to 12 hours; 4) The static liquid was centrifuged at 8000 rpm for 20 min, washed three times with anhydrous methanol, and dried at 50° C. under vacuum conditions for 12 h to obtain γ-CD-MOFs.

5. An albendazole-delivered anticancer drug prepared by the method according to any one of claims 1 to 4.

Citation Information

Patent Citations

  • Rapid synthesis method of cyclodextrin-metal organic framework material

    CN107151329A

  • Preparation and inclusion method of albendazole inclusion complex tablets

    CN107669650A

  • Cyclodextrin-metal organic framework composition for improving solubility of valsartan

    CN110314239A

  • Paclitaxel dry powder inhalant as well as preparation method and application thereof

    CN116763764A

  • Methyl-beta-cyclodextrin and albendazole inclusion compound and preparation method thereof

    CN117357664A

Cited By

  • Metal organic framework-albendazole drug delivery system and preparation method thereof

    CN120643565A

  • Metal-organic framework- albendazole drug delivery system and method of making the same

    CN120643565B